.png)
.png)
Latest news from BIA
BIA welcomes Minister’s Reassurance on the Patents (Amendment) (EU Exit) Regulations 2018
The Government last night committed to further consultation with the BIA on the UK’s future Intellectual Property rights regime in the event of a ‘no deal’ Brexit following concerns raised in the House of Lords.
2018 a record year for UK biotech fundraising
New figures published today (Thursday 24 January 2019) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017. The data is presented in the report Confident capital: backing UK biotech and launched by the Exchequer Secretary to the Treasury, Robert Jenrick MP, at the BIA's Strategic Technologies event in central London today.
BIA response to Health Secretary's plan to contain and control AMR
Steve Bates OBE, CEO of the BIA said: “It’s great to see the UK government and NHS committed to exploring a new payment model for antibiotics in our market. The UK took a lead in putting Anti Microbial Resistance (AMR) on the global agenda and it’s really good to see it taking a first mover advantage on innovative pricing and reimbursement for AMR.
BIA welcomes the announcement of Nicola Blackwood as new Under-Secretary of State for Health
The BIA welcomes the announcement of Nicola Blackwood as new Parliamentary Under-Secretary of State for Health. BIA CEO, Steve Bates OBE, said: “As a former health minister and former chair of the science and technology committee, and serving as a board member of Eagle Genomics, Nicola knows our sector well and is well-placed to hit the ground running. We had a strong relationship with Nicola when she was minister for health, and we look forward to working with her to ensure the UK stays a world-leader in the life sciences.”
The AMR Centre secures £2.3m funding boost
The AMR Centre has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.
DISCOVERY PARK CHAIRMAN MARTINO PICARDO SHARES INSIGHT AT CONFERENCES
Science park leader to talk at UKSPA, Knowledge Exchange meeting & BioIntegrates
Arecor receives regulatory approval to initiate phase I clinical trial for ultra-rapid acting insulin product
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
Apply to present at the 2019 Babraham Investor Conference
Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference
Guest blog | Repositive | Two opportunities for biopharmas to enhance their preclinical cancer research at AACR 2019
Three initiatives that are accelerating the development of personalised cancer treatments to the clinic How to overcome the challenges biopharmas face when sourcing preclinical cancer models A recent meta-analysis of clinical trials put the success rate for therapies in cancer indications progressing from first-in-human to approval at just 3.4%. That means a staggering 96.6% of cancer therapies fail during the clinical stages of drug development. In this blog post we discuss one of the key issues hindering preclinical cancer drug development and explore the latest initiatives that are helping to advance new cancer treatments to the clinic.
CEO Update | Monday 18 March 2019
An interesting first at the WHO this week as it convenes its first expert advisory committee on developing global standards for the governance and oversight of human genome editing. I’ve pulled some thoughts together on it, the Nature letter that made headlines last week and a UK perspective in a blog post here. Parliament will again focus on Brexit this week, in the run up to the European Council meeting on Thursday and Friday. There may, or may not, be another parliamentary vote ahead of the discussion on Thursday where the Prime Minister is expected to ask for an extension to the Article 50 period.
The WHO, gene editing and ethics | BIA CEO, Steve Bates OBE
The World Health Organisation is today convening its first expert advisory committee on developing global standards for the governance and oversight of human genome editing. The aim of the two-day meeting, in Geneva, is to examine the scientific, ethical, social and legal challenges of gene-editing and create guidelines and standards for it. The meeting follows a call last week by some 16 leading scientists from 7 countries: USA; China; Canada; France; Germany; Italy and New Zealand for a global moratorium on heritable genome editing.
Guest Blog | SynbiTECH 2019
SynbiTECH 2019 | June 24-25th, QEII Centre, London SynbiTECH 2019 is the only international forum focused on synthetic biology, taking place in the UK in 2019. The event will address the opportunities and challenges associated with building a multibillion-dollar synthetic biology industry that will underpin the fast-growing bioeconomy. The event is designed for senior business leaders from start-ups to multinationals, investors and policy makers.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
